372
Views
15
CrossRef citations to date
0
Altmetric
Original Article

Personal Costs of Visual Impairment by Different Eye Diseases and Severity of Visual Loss

, , &
Pages 339-344 | Received 29 Oct 2007, Accepted 23 May 2008, Published online: 08 Jul 2009

REFERENCES

  • Keeffe J E, Lam D, Cheung A, Dinh T, McCarty C A. Impact of impairment on functioning. Australia and NZJ. Ophthalmol 1998; 26(Supp 1)S16–S18
  • Ivers R Q, Cumming R G, Mitchell P, Attebo K. Visual impairment and falls in older adults: The Blue Mountains Eye Study. J Am Geriatr Soc 1998; 46(1)58–64
  • McCarty C A, Nanjan M B, Taylor H R. Vision impairment predicts 5 year mortality. Br J Ophthalmol 2001; 85(3)322–326
  • Livingston P M, McCarty C A, Taylor H R. Knowledge, attitudes, and self care practices associated with age related eye disease in Australia. Br J Ophthalmol 1998; 82(7)780–785
  • Jacobs J M, Hammerman-Rozenberg R, Maaravi Y, Cohen A, Stessman J. The impact of visual impairment on health, function and mortality. Aging Clin Exp Res 2005; 17(4)281–286
  • Horowitz A, Reinhardt J P, Kennedy G J. Major and subthreshold depression among older adults seeking vision rehabilitation services. Am J Geriatr Psychiatry 2005; 13(3)180–187
  • Taylor H R, Pezzullo M L, Keeffe J E. The economic impact and cost of visual impairment in Australia. Br J Ophthalmol 2006; 90(3)272–275
  • Wang J J, Foran S, Mitchell P. Age-specific prevalence and causes of bilateral and unilateral visual impairment in older Australians: The Blue Mountains Eye Study. Clin Experiment Ophthalmol 2000; 28(4)268–273
  • Rein D B, Zhang P, Wirth K E, Lee P P, Hoerger T J, McCall N, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol 2006; 124(12)1754–1760
  • Kaiser P K, Do D V. Ranibizumab for the treatment of neovascular AMD. Int J Clin Pract 2007; 61(3)501–509
  • Takeda A L, Colquitt J L, Clegg A J, Jones J. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: A systematic review. Br J Ophthalmol 2007
  • Jonas J B. Intravitreal triamcinolone acetonide for diabetic retinopathy. Dev Ophthalmol 2007; 39: 96–110
  • Tschernutter M, Schlichtenbrede F C, Howe S, Balaggan K S, Munro P M, Bainbridge J W, et al. Long-term preservation of retinal function in the RCS rat model of retinitis pigmentosa following lentivirus-mediated gene therapy. Gene Ther 2005; 12(8)694–701
  • Javitt J C, Zhou Z, Willke R J. Association between vision loss and higher medical care costs in Medicare beneficiaries costs are greater for those with progressive vision loss. Ophthalmology 2007; 114(2)238–245
  • Meads C, Hyde C. What is the cost of blindness?. Br J Ophthalmol 2003; 87(10)1201–1204
  • Frick K D, Foster A. The magnitude and cost of global blindness: An increasing problem that can be alleviated. Am J Ophthalmol 2003; 135(4)471–476
  • Smith A F, Smith J G. The economic burden of global blindness: A price too high!. Br J Ophthalmol 1996; 80(4)276–277
  • Shamanna B R, Dandona L, Rao G N. Economic burden of blindness in India. Indian J Ophthalmol 1998; 46(3)169–172
  • Frick K D, Gower E W, Kempen J H, Wolff J L. Economic impact of visual impairment and blindness in the United States. Arch Ophthalmol 2007; 125(4)544–550
  • Taylor H R. LXIII Edward Jackson Memorial Lecture: Eye care: Dollars and sense. Am J Ophthalmol 2007; 143(1)1–8
  • Hamer H M, Spottke A, Aletsee C, Knake S, Reis J, Strzelczyk A, et al. Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany. Epilepsia 2006; 47(12)2165–2172
  • Stark R, Konig H H, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics 2006; 24(8)797–814
  • Goossens M E, Rutten-van Molken M P, Vlaeyen J W, van der Linden S M. The cost diary: A method to measure direct and indirect costs in cost-effectiveness research. J Clin Epidemiol 2000; 53(7)688–695
  • Chou S L, Lamoureux E, Keeffe J. Methods for measuring personal costs associated with vision impairment. Ophthalmic Epidemiol 2006; 13(6)355–363
  • Bibby S A, Maslin E R, McIlraith R, Soong G P. Vision and self-reported mobility performance in patients with low vision. Clin Exp Optom 2007; 90(2)115–123
  • Hassan S E, Lovie-Kitchin J E, Woods R L. Vision and mobility performance of subjects with age-related macular degeneration. Optom Vis Sci 2002; 79(11)697–707
  • Taylor H R, Keeffe J E, Vu H T, Wang J J, Rochtchina E, Pezzullo M L, et al. Vision loss in Australia. Med J Aust 2005; 182(11)565–568

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.